ULCERATIVE-NECROTIZING ANGIITIS ON A BACKGROUND OF RECEPTION OF LENVATINIB IN THYROID CANCER
- Authors: Orlova E.V.1, Grabovskaya O.V1, Smirnova L.M1, Shestakova L.A1, Melikova N.I1, Kayumova L.N1
-
Affiliations:
- Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 22, No 1-2 (2019)
- Pages: 29-32
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/42933
- DOI: https://doi.org/10.17816/dv42933
- ID: 42933
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina V. Orlova
Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: orlovaderm@yandex.ru
MD, PhD, docent of the Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119435, Russian Federation 119435, Moscow, Russian Federation
O. V Grabovskaya
Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)119435, Moscow, Russian Federation
L. M Smirnova
Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)119435, Moscow, Russian Federation
L. A Shestakova
Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)119435, Moscow, Russian Federation
N. I Melikova
Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)119435, Moscow, Russian Federation
L. N Kayumova
Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)119435, Moscow, Russian Federation
References
- Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 2006; 91(8): 2892-9.
- Sgouros G., Kolbert K.S., Sheikh A., Pentlow K.S., Mun E.F., Barth A., et al. Patient-specific dosimetry for I131 thyroid cancer therapy using I124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J. Nucl. Med. 2004; 45(8): 1366-72.
- Каприн А.Д., Старинский В.В., Петров Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИЦ радиологии Минздрава России; 2018. http://www.oncology.ru/service/statistics; https://www.rakfond.org/2018/10/19/cancer-statistics-incidence-and-mortality_ru/
- Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998; 83(12): 2638-48.
- Sciuto R., Romano L., Rea S., Marandino F., Sperduti I., Maini C.L. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann. Oncol. 2009; 20(10): 1728-35.
- Pacini F., Castagna M.G. Approach to and treatment of differentiated thyroid carcinoma. Med. Clin. North Am. 2012; 96(2): 369-83.
- Xing M., Haugen B., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013; 381(9871): 1058-69.
- Amin A., Badwey A., El-Fatah S. Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin. Nucl. Med. 2014; 39(2): 142-6.
- Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483): 1357-60.
- Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol. Cell Endocrinol. 2010; 321(1): 20-8.
- Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003; 284(1): 99-110.
- Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008; 14(17): 5459-65.
- Grande E., Diez J.J., Zafon C., Capdevila J. Thyroid cancer: molecular aspects and new therapeutic strategies. J. Thyroid. Res. 2012; 2012: 847108.